Investor Relations

Press Releases

Date Title/Summary View
Toggle Summary Vericel to Present at Multiple Upcoming Investor Conferences
  CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the
View HTML
Toggle Summary Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has designated the
View HTML
Toggle Summary Vericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the first implant of MACI ® (autologous cultured chondrocytes on
View HTML
Toggle Summary Vericel Corporation Announces Exercise of Underwriters' Over-Allotment Option and Closing of $20 Million Offering of Common Stock
  CAMBRIDGE, Mass., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation ( VCEL ), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it has closed its previously announced underwritten public offering
View HTML
Toggle Summary Vericel Corporation Prices $17 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the pricing of its previously announced underwritten public offering
View HTML
Toggle Summary Vericel Corporation Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it intends to offer and sell shares of its common stock in an
View HTML
Toggle Summary FDA Approves MACI for the Treatment of Symptomatic Cartilage Defects of the Knee in Adults
First Tissue-Engineered Autologous Cellularized Scaffold Product Approved by the FDA Conference Call Today at 9:00am Eastern Standard Time CAMBRIDGE, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the
View HTML
Toggle Summary Vericel to Present at 28th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the
View HTML
Toggle Summary Additional Pre-Specified Secondary Results on the Reduction of Ventricular Arrhythmias Presented at AHA from Vericel's Positive Phase 2b ixCELL‑DCM Clinical Trial of Ixmyelocel-T
CAMBRIDGE, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the presentation of additional pre‑specified secondary endpoint results from the
View HTML
Toggle Summary Vericel Reports Third-Quarter 2016 Financial Results
Total Revenues of $10.9 Million Reported for the Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of severe diseases and conditions,
View HTML